Comparative Pharmacology
Head-to-head clinical analysis: AMBIEN versus VALMID.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMBIEN versus VALMID.
AMBIEN vs VALMID
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Positive allosteric modulator of GABA-A receptors, enhancing the inhibitory effects of GABA. Binds selectively to the alpha-1 subunit, producing sedative, hypnotic, and anxiolytic effects.
Valproate increases gamma-aminobutyric acid (GABA) concentrations in the brain either by inhibiting GABA transaminase or by increasing glutamic acid decarboxylase activity, thereby enhancing inhibitory neurotransmission.
5-10 mg orally once daily at bedtime, maximum 10 mg/day.
250 mg orally three times daily.
None Documented
None Documented
Terminal elimination half-life is approximately 2.6 hours (range 1.4–4.5 hours). In elderly patients, half-life may be prolonged to about 2.9 hours. In patients with hepatic cirrhosis, half-life is significantly increased (up to 9.8 hours).
Terminal elimination half-life is 2-4 hours in adults with normal renal function; prolonged to 10-20 hours in severe renal impairment (CrCl <30 mL/min), necessitating dose adjustment.
Primarily renal excretion: approximately 56% of the dose is recovered in urine as metabolites (including 5% unchanged drug). Fecal excretion accounts for about 34% of the dose. Small amounts are excreted in bile.
Renal excretion accounts for >90% of elimination, primarily as unchanged drug via glomerular filtration and tubular secretion. Biliary/fecal excretion is minimal (<5%).
Category C
Category C
Sedative-Hypnotic
Sedative-Hypnotic